Better regulation for better clinical trials - some hope?

Good randomized controlled trials (RCTs) provide reliable evidence that enables informed changes in healthcare practice. It must be made easier to do good RCTs to inform future care. The Good Clinical Trials Collaborative, is a global community initiative led by Professor Martin Landray that has developed new guidance to promote and enable good RCTs and will be the focus of this talk.

Martin Landray is Professor of Medicine and Epidemiology at Oxford Population Health, an Honorary Consultant Physician at Oxford University Hospitals NHS Foundation Trust and the founding Deputy Director of the University of Oxford’s Big Data Institute.

Professor Landray’s work seeks to further understanding of the determinants of common diseases chiefly through the design, conduct and analysis of efficient, large-scale clinical trials. He has led a series of major clinical trials, chiefly of treatments for cardiovascular and kidney disease. He co-led the RECOVERY trial, the world’s largest trial of potential treatments for COVID-19, publishing definitive results for multiple treatments.

He leads Protas, a not-for-profit organisation focused on smarter randomised trials for better public health. In 2021, he was appointed to the Pandemic Preparedness Partnership leading to the publication of the G7 100 Days Mission to Respond to Future Pandemic Threats. He was also elected Fellow of the Academy of Medical Sciences and was knighted for services to public health and science.